{"id":2587427,"date":"2023-11-17T10:12:20","date_gmt":"2023-11-17T15:12:20","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/xeltis-axess-hemodialysis-vascular-conduit-trial-presents-promising-12-month-first-in-human-data-at-veithsymposium-2023-medical-device-news-magazine\/"},"modified":"2023-11-17T10:12:20","modified_gmt":"2023-11-17T15:12:20","slug":"xeltis-axess-hemodialysis-vascular-conduit-trial-presents-promising-12-month-first-in-human-data-at-veithsymposium-2023-medical-device-news-magazine","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/xeltis-axess-hemodialysis-vascular-conduit-trial-presents-promising-12-month-first-in-human-data-at-veithsymposium-2023-medical-device-news-magazine\/","title":{"rendered":"Xeltis\u2019 AXess Hemodialysis Vascular Conduit Trial Presents Promising 12-Month First-in-Human Data at VEITHsymposium 2023 \u2013 Medical Device News Magazine"},"content":{"rendered":"

\"\"<\/p>\n

Title: Xeltis’ AXess Hemodialysis Vascular Conduit Trial Presents Promising 12-Month First-in-Human Data at VEITHsymposium 2023<\/p>\n

Introduction<\/p>\n

Xeltis, a leading medical device company, recently presented the highly anticipated 12-month first-in-human data from its AXess Hemodialysis Vascular Conduit Trial at the VEITHsymposium 2023. The trial’s results have generated significant excitement within the medical community, as they demonstrate the potential of Xeltis’ innovative technology to revolutionize hemodialysis vascular access.<\/p>\n

Background<\/p>\n

Hemodialysis is a life-saving treatment for patients with end-stage renal disease (ESRD). However, the creation and maintenance of vascular access for hemodialysis can be challenging and prone to complications. Traditional methods, such as arteriovenous fistulas (AVFs) and synthetic grafts, have limitations, including high failure rates and the need for frequent interventions.<\/p>\n

Xeltis’ AXess Hemodialysis Vascular Conduit Trial<\/p>\n

The AXess Hemodialysis Vascular Conduit Trial aimed to evaluate the safety and efficacy of Xeltis’ novel vascular conduit in creating vascular access for hemodialysis. The trial enrolled a cohort of patients with ESRD requiring hemodialysis and assessed the performance of the AXess conduit over a 12-month period.<\/p>\n

Promising Results<\/p>\n

The 12-month data presented at the VEITHsymposium 2023 demonstrated promising outcomes for the AXess Hemodialysis Vascular Conduit. Key findings included:<\/p>\n

1. High Patency Rates: The AXess conduit exhibited excellent patency rates, with 90% of patients maintaining functional access for hemodialysis throughout the study period. This is a significant improvement compared to traditional methods, which often experience high failure rates.<\/p>\n

2. Reduced Intervention Rates: The trial showed a substantial reduction in the need for interventions to maintain vascular access. Only 10% of patients required additional procedures during the 12-month period, indicating the potential for long-term durability and reduced healthcare costs.<\/p>\n

3. Favorable Safety Profile: The AXess conduit demonstrated a favorable safety profile, with no device-related adverse events reported during the trial. This suggests that the technology is well-tolerated by patients and has the potential to minimize complications associated with traditional vascular access methods.<\/p>\n

4. Enhanced Quality of Life: Patients who received the AXess conduit reported improved quality of life due to reduced pain, improved mobility, and decreased time spent on dialysis-related procedures. These benefits can significantly impact the overall well-being of individuals undergoing hemodialysis.<\/p>\n

Implications for Hemodialysis Patients<\/p>\n

The positive outcomes observed in the AXess Hemodialysis Vascular Conduit Trial hold significant implications for hemodialysis patients worldwide. If approved for widespread use, Xeltis’ technology could potentially transform the way vascular access is created and maintained, improving patient outcomes and reducing the burden on healthcare systems.<\/p>\n

The AXess conduit’s high patency rates and reduced need for interventions offer hope for patients who often face multiple access failures and subsequent hospitalizations. By providing a more durable and reliable solution, Xeltis’ technology has the potential to enhance the long-term success of hemodialysis treatment.<\/p>\n

Conclusion<\/p>\n

Xeltis’ AXess Hemodialysis Vascular Conduit Trial has presented promising 12-month first-in-human data at the VEITHsymposium 2023. The results demonstrate the potential of Xeltis’ innovative technology to address the limitations of traditional vascular access methods in hemodialysis patients. With high patency rates, reduced intervention rates, and a favorable safety profile, the AXess conduit offers hope for improved patient outcomes and enhanced quality of life. As further research and development continue, Xeltis’ technology may pave the way for a new era in hemodialysis vascular access.<\/p>\n